GSK Earnings

GSK reported its earnings on 2026-04-29, showcasing a revenue of 10.28B against an estimate of 10.19B, resulting in a 0.89% surprise. The EPS was 1.24, surpassing the expected 1.16 by 6.9%. The stock experienced a -5.64% price change on the earnings day and a -6.55% change over the next five days, reflecting market reactions to the results.

Following GSK's earnings announcement on 2026-04-29, the stock price moved by -5.64% on the day of the release. Over the subsequent five days, it saw a -6.55% change. Historically, GSK's stock price tends to shift by an average of -2.92% in the 10 days leading up to earnings and 1.29% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate GSK's annual revenue to reach 8.38B, while the EPS is projected at 1.27. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GSK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GSK's stock price typically moves by -2.92% in the 10 days before its earnings and 1.29% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 1.27 and revenue of 8.38B.

The earnings call summary and Q&A indicate positive sentiment. Specialty medicines and HIV portfolios show promising growth, supported by strong pipeline developments. The 6% dividend increase and strategic focus on operational efficiency bolster confidence. Despite some uncertainties, optimistic guidance and new product launches, such as Exdensur, provide a positive outlook. The market reaction is expected to be positive, with a 2% to 8% increase in stock price over the next two weeks.